Mitchell G. Ayers
Immunology and Microbiology · Purdue University West Lafayette
Publications
59
Citations
60
Est. group size
~5
Recurring co-author estimate
Active years
12
Publishing since 2014
Mitchell G. Ayers studies how breast cancer cells spread to other parts of the body (metastasis) and evade the immune system. His work looks at specific proteins involved in cell signaling—such as SHP2, FGFR1, and PDGFR—and how they affect tumor growth, drug resistance, and immune suppression in breast cancer models. The research combines molecular biology techniques with cancer immunology to identify potential drug targets.
Publication output was minimal or absent before 2022, then rose sharply in 2023 with a large cluster of related outputs, followed by a decline in 2024-2025, suggesting a burst of activity tied to specific projects rather than steady long-term output.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- PBRM1-Dependent PBAF Targeting is Required for EMT and Metastasis in Breast Cancer
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Abstract 6049: Fibroblast growth factor receptor modulates IFN-γ response in breast cancer
Cancer Research · 2025
- The highly metastatic 4T1 breast carcinoma model possesses features of a hybrid epithelial/mesenchymal phenotype
Disease Models & Mechanisms · 2024
- Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer
Communications Biology · 2024
- Abstract B066: PDGFR upregulation functions as a bypass mechanism contributing to FGFR inhibitor resistance in metastatic breast cancer
Cancer Research · 2024
- Abstract PO2-18-06: Targeting fibroblast growth factor receptor (FGFR1) expression through G-quadruplex stabilization inhibits metastatic breast cancer
Cancer Research · 2024
- Data from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Data from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Supplementary Information SI1 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Supplementary Tables S1-S7 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Supplementary Figure S9 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Supplementary Figure S5 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Supplementary Figure S8 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Supplementary Figure S11 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Supplementary Figure S2 from Tumor Cell–Autonomous SHP2 Contributes to Immune Suppression in Metastatic Breast Cancer
2023
- Cancer Research×3
- Disease Models & Mechanisms×1
- Cancer Immunology Immunotherapy×1
- Cancer & Metabolism×1
- Communications Biology×1
- Gregory M. Cresswell
Immunology and Microbiology · Purdue University West Lafayette
- Jinmin Miao
Immunology and Microbiology · Purdue University West Lafayette
- Hao Chen
Immunology and Microbiology · Purdue University West Lafayette
- Megan Duggan
Immunology and Microbiology · The Ohio State University
- Emily Schwarz
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile